Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease ...